Abstract: Described is an aqueous liquid oral gliptin composition comprising a gliptin or a pharmaceutically acceptable salt or ester thereof, and an artificial non-sugar alcohol sweetening agent, the solution having a sugar alcohol content of less than 25 w/v %. The composition has an improved taste and stability as compared to known compositions. Also described is a method comprising the steps of heating 80-95 v/v % of the water to 40-65° C., admixing the antioxidant, and, if present, the chelating agent and buffering agent, optionally, cooling down to 25-35° C.

Abstract: Described is a method for the preparation of an oral levothyroxine composition, comprising the steps of combining levothyroxine or a salt thereof, a water-miscible organic solvent or a sugar alcohol and water, adjusting the pH to at least 8 providing a basic aqueous medium, dissolving the levothyroxine in the basic aqueous medium to yield a levothyroxine solution, and lowering the pH of the levothyroxine solution to between 3.5-4.9. also described is an oral levothyroxine composition obtainable by the said method and its use as a medicament.

Abstract: Described is an aqueous liquid oral gliptin composition comprising a gliptin or a pharmaceutically acceptable salt or ester thereof, and an artificial non-sugar alcohol sweetening agent, the solution having a sugar alcohol content of less than 25 w/v %. The composition has an improved taste and stability as compared to known compositions. Also described is a method comprising the steps of heating 80-95 v/v % of the water to 40-65° C., admixing the antioxidant, and, if present, the chelating agent and buffering agent, optionally, cooling down to 25-35° C.

Abstract: Described is a method for the preparation of an oral levothyroxine composition, comprising the steps of combining levothyroxine or a salt thereof, a water-miscible organic solvent or a sugar alcohol and water, adjusting the pH to at least 8 providing a basic aqueous medium, dissolving the levothyroxine in the basic aqueous medium to yield a levothyroxine solution, and lowering the pH of the levothyroxine solution to between 3.5-4.9. also described is an oral levothyroxine composition obtainable by the said method and its use as a medicament.

Abstract: Described is a method for the preparation of an oral levothyroxine composition, comprising the steps of combining levothyroxine or a salt thereof, a water-miscible organic solvent or a sugar alcohol and water, adjusting the pH to at least 8 providing a basic aqueous medium, dissolving the levothyroxine in the basic aqueous medium to yield a levothyroxine solution, and lowering the pH of the levothyroxine solution to between 3.5-4.9. also described is an oral levothyroxine composition obtainable by the said method and its use as a medicament.

Abstract: Disclosed herein are pharmaceutical compositions for oral administration. The compositions are premixed aqueous suspensions of methylprednisolone and/or homogeneous aqueous suspensions of methylprednisolone. The pharmaceutical compositions include either about 2 mg/ml to about 4 mg/ml methylprednisolone or, alternatively, about 3 mg/ml to about 4 mg/ml methylprednisolone. The pharmaceutical compositions are exceptionally stable upon storage and are palatable.

Abstract: The invention provides a sustained release composition that; (1). Is free of initially increased drug delivery that occurs (in sustained release systems containing the water soluble drug venlafaxine HCl, known as burst phenomenon, by using a functional core partially or totally coated by a functional coating layer or film. (2). Delivers the drug substance within 24 hours and is therefore suitable for once daily administration of the said drug substance. (3). Exhibits linearity between the strength dosage form and the (total mass of the dosage form, by proportional increase of the amounts of the drug substance and the excipients in the formulation. (4). Is possible to be divided in smaller doses, without affecting the release of the drug substance. The invention provides a sustained release capsule formulation containing an appropriate number of functional complex mini tablets comprising of: (1).

Abstract: The invention provides a sustained release composition that; 1. Is free of initially increased drug delivery that occurs (in sustained release systems containing the water soluble drug venlafaxine HCl, known as burst phenomenon, by using a functional core partially or totally coated by a functional coating layer or film. 2. Delivers the drug substance within 24 hours and is therefore suitable for once daily administration of the said drug substance. 3. Exhibits linearity between the strength dosage form and the (total mass of the dosage form, by proportional increase of the amounts of the drug substance and the excipients in the formulation. 4. Is possible to be divided in smaller doses, without affecting the release of the drug substance. The invention provides a sustained release capsule formulation containing an appropriate number of functional complex mini tablets comprising of: I.